Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Waldenstrom Macroglobulinemia: early-phase trial registry
16 of 35 indexed Waldenstrom Macroglobulinemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 16 currently recruiting · #435 of 28,707 conditions by registered trial count
Waldenstrom Macroglobulinemia: 35 US clinical trials tracked, 16 recruiting.
Waldenstrom Macroglobulinemia is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 3 of these trials.
Enrollment posture brief
Registry condition waldenstrom-macroglobulinemia
OPEN 16 | RECR 46% | LATE 1 | EARLY 27 | RANK #435 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Substance Use Disorders (46% recruiting · 94 trials)
Waldenstrom Macroglobulinemia lists 16 open slots (46% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Waldenstrom Macroglobulinemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Waldenstrom Macroglobulinemia is recruiting above its size-band peers.
16 of 35 indexed trials (45.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Waldenstrom Macroglobulinemia trials is spread across many organizations.
Dana-Farber Cancer Institute accounts for 3 of 35 trials (8.6%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Waldenstrom Macroglobulinemia enrolment sits around 60 participants.
Median target enrolment is 60 among the 35 trials that report a genuine target (sentinel values excluded). 20 of those (57.1%) plan for fewer than 100 participants.
-
Waldenstrom Macroglobulinemia research is mostly interventional.
29 interventional and 6 observational studies make up this index (82.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
NCT02269592
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Heart, Lung, and Blood Institute (NHLBI)
NCT00923507
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Janssen Research & Development
NCT01804686
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06340737
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences
NCT05602363
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
BeiGene
NCT05640102
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Mayo Clinic
NCT06151730
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger
NCT05544019
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
NCT04840602
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical
NCT04775745
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Massachusetts General Hospital
NCT06561347
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
NCT05734495
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Memorial Sloan Kettering Cancer Center
NCT07231952
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
UNC Lineberger Comprehensive Cancer Center
NCT06860880
Loncastuximab Tesirine in WM
Shayna Sarosiek, MD
NCT05190705
Epcoritamab in Previously Treated WM
Gottfried von Keudell, MD PhD
NCT06510491
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
National Cancer Institute (NCI)
NCT00039676
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
NCT05024045
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT03162536
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta
NCT05020678
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Cellectar Biosciences
NCT02952508
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
BeOne Medicines
NCT05952037
Rifaximin in Patients With Monoclonal Gammopathy
Emory University
NCT03820817
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Kami Maddocks, MD
NCT01479842
Ibrutinib + Venetoclax in Untreated WM
Dana-Farber Cancer Institute
NCT04273139
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT02339922
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Bio-Path Holdings
NCT04072458
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
NCT04464200
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
Shayna Sarosiek, MD
NCT05065554
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00105001
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Massachusetts General Hospital
NCT04830046
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
University of Arkansas
NCT00083707
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co.
NCT04018248
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
TG Therapeutics
NCT03364231
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT04450069
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 14 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Waldenstrom Macroglobulinemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Waldenstrom Macroglobulinemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Waldenstrom Macroglobulinemia page
35 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Waldenstrom Macroglobulinemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Waldenstrom Macroglobulinemia trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Waldenstrom Macroglobulinemia condition card totals 35 registered trials; most-linked intervention Pirtobrutinib; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.